Pricing Availability   Qty

Save up to 40% on RUO Reagents with BIOSPRING24 (see details)

Description: COMT inhibitor
Chemical Name: 3,5-Dinitrocatechol
Purity: ≥99% (HPLC)
Citations (2)
Literature (1)

Biological Activity for OR-486

OR-486 is a potent and selective inhibitor of catechol-O-methyl-transferase.

Technical Data for OR-486

M. Wt 200.11
Formula C6H4N2O6
Storage Store at RT
Purity ≥99% (HPLC)
CAS Number 7659-29-2
PubChem ID 3870203
Smiles OC1=CC(=CC(=C1O)[N+]([O-])=O)[N+]([O-])=O

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for OR-486

Solvent Max Conc. mg/mL Max Conc. mM
ethanol 20.01 100
DMSO 20.01 100

Preparing Stock Solutions for OR-486

The following data is based on the product molecular weight 200.11. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 5 mL 24.99 mL 49.97 mL
5 mM 1 mL 5 mL 9.99 mL
10 mM 0.5 mL 2.5 mL 5 mL
50 mM 0.1 mL 0.5 mL 1 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Product Datasheets for OR-486

Certificate of Analysis / Product Datasheet
Select another batch:

References for OR-486

References are publications that support the biological activity of the product.

Mannisto and Kaakola (1990) Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson's disease. Pharmacol.Toxicol. 66 317 PMID: 2196554

Borgulya et al (1989) Catechol-O-methyltransferase-inhibiting pyrocatechol derivatives: synthesis and structure-activity studies. Helv.Chim.Acta 72 952

If you know of a relevant reference for OR-486, please let us know.

View Related Products by Product Action

View all Catechol O-Methyltransferase Inhibitors

Keywords: OR-486, OR-486 supplier, Catechol, O-methyl, transferase, COMT, inhibitors, inhibits, Adrenergic, Related, Compounds, Dopaminergic-Related, O-Methyltransferase, 0483, Tocris Bioscience

2 Citations for OR-486

Citations are publications that use Tocris products. Selected citations for OR-486 include:

Ciszek et al (2016) Persistent catechol-O-methyltransferase-dependent pain is initiated by peripheral β-andrenergic receptors. Anesthesiology 124 1122 PMID: 26950706

Oróstica et al (2014) OE increases cAMP in the oviductal secretory cells through a nongenomic mechanism. Reproduction 148 285 PMID: 25038866

Do you know of a great paper that uses OR-486 from Tocris? Please let us know.

Reviews for OR-486

There are currently no reviews for this product. Be the first to review OR-486 and earn rewards!

Have you used OR-486?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.